【DaYan BioMedical*】The Company's Board of Directors Approved the Consolidated Financial Statements for Q1 2026
Key facts
- 【DaYan BioMedical*】The Company's Board of Directors Approved the Consolidated Financial Statements for Q1 2026
- DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.
- Source: PR Times
- Date: May 7, 2026
Direct answer
DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.
- Citation
- 【DaYan BioMedical*】The Company's Board of Directors Approved the Consolidated Financial Statements for Q1 2026 (May 7, 2026), PR Times
- Source
- PR Times
- Date
- May 7, 2026
DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.
📋 Article Processing Timeline
- 📰 Published: May 7, 2026 at 09:00
- 🔍 Collected: May 8, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 8, 2026 at 09:12 (1h 12m after Collected)
2. Date of approval by the audit committee: 2026/05/07
3. Reporting period of financial report or self-compiled financial information for the year
from (YYYY/MM/DD) to (YYYY/MM/DD): 2026/01/01~2026/12/31
4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NTD): 463,842
5. Cumulative operating gross profit (gross loss) from January 1 to the end of this period (in thousands of NTD): 278,740
6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands of NTD): 62,176
7. Cumulative net profit (net loss) before tax from January 1 to the end of this period (in thousands of NTD): 140,409
8. Cumulative net profit (net loss) for the current period from January 1 to the end of this period (in thousands of NTD): 104,355
9. Cumulative net profit (loss) attributable to owners of parent from January 1 to the end of this period (in thousands of NTD): 104,355
10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NTD): 0.13
11. Total assets at the end of the period (in thousands of NTD): 6,115,807
12. Total liabilities at the end of the period (in thousands of NTD): 597,910
13. Equity attributable to owners of parent at the end of the period (in thousands of NTD): 5,517,897
14. Other matters that need to be specified: None
FAQ
What are the key facts in this article?
DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.
What is the direct answer?
DaYan BioMedical's Board of Directors has approved the consolidated financial statements for the first quarter of 2026 (115 ROC calendar). Key financial indicators show robust performance, including operating revenue of NT$463.842 million, pre-tax net profit of NT$140.409 million, and basic EPS of NT$0.13.
What is the source and date?
PR Times: https://mops.twse.com.tw/material/twse-7780-2026-05-07-5e7e4e2d | May 7, 2026